Pharma Forum 2026

Fish & Richardson Principals Louis Fogel and Peng Lin will speak at the 2026 IP Forefront Pharma Forum, being held September 16-18 in Shanghai, China.

For over a decade, the annual IP Forefront Pharma Forum has served as an influential and forward-looking event in the field of pharma IP in China and globally. This year's forum will follow the theme "Innovation, Protection, Globalization: A New Ecosystem for Pharmaceutical IP." Session details are below.

The Boundaries of Written Description and Enablement: Lessons from Seagen v. Daiichi | Louis Fogel

On December 2, 2025, the U.S. Court of Appeals for the Federal Circuit rendered a decision shaking the global antibody-drug conjugate (ADC) industry — holding Seagen's U.S. Patent No. 10,808,039 invalid for lack of written description and enablement under 35 U.S.C. § 112, overturning a prior Texas jury verdict awarding Seagen $41.8 million USD in damages and ongoing royalties.

• Deep-dive review of the Seagen v. Daiichi case 
• Far-reaching implications of U.S. written description/enablement requirements for conjugate drug platform patents 

Hot Topics in U.S. Patent Drafting and Prosecution: Patent Drafting, Examination, and Post-Grant Review Trends | Peng Lin 

This session will cover:  

• The new landscape for enablement and written description  
• The latest rules for obviousness and obviousness-type double patenting (ODP)
• New rules for inventorship and disclosure of AI-assisted inventions
• New trends in Patent Trial and Appeal Board/inter partes review proceedings 

For more information, click here.